Medro review
The lead figure has a one-time code applied. The standing rates are $199 and $299.
The verdict
Medro leads with $99 for semaglutide and $199 for tirzepatide. Both carry a flat first-order code. Without it, the rates are $199 and $299. The page strikes those through beside the lead.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- States
- 50
- From
- From $199/mo
- Dose published
- No
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Pharmacy
- Not named
- Availability
- All 50 states
Medro is a telehealth brand covering weight loss, skin, hair and more. It sells compounded semaglutide and tirzepatide by weekly injection. Brand-name GLP-1s are also offered. Coverage is stated as all 50 states.
Who writes the prescription, and what do they see?
A partner medical group provides the clinical care. Licensed clinicians review each intake. Neither the group nor its clinicians are named. A prescription precedes shipping.
Support is stated as unlimited and available around the clock. Follow-up and care coordination are listed as included. No membership is required. A licensed pharmacy partner fills the order and is not named.
What happens when the dose goes up?
The page states the same price at every dose. Its footnote then lists dose among seven factors that may change the final price. Those two statements conflict. The final price is shown before checkout, after a prescription.
What the price includes
The code applies to the first plan only. After that, semaglutide is $199 and tirzepatide is $299. Six months of semaglutide at $199 is $1,194. Six months of tirzepatide at $299 is $1,794. Supply duration is named as a price factor but not priced.
What it claims, and what it cites
Both lines are compounded in the U.S. The page states the FDA does not evaluate compounded medications. Each formulation includes glycine and vitamin B12. The pharmacy is not named.
Where it holds up, and where it does not
- Strength: The struck standing rate sits beside the lead
- Strength: Same price at every dose, per the page
- Strength: No membership is required to buy
- Strength: Coverage stated as all 50 states
- Limitation: The lead figure includes a one-time code
- Limitation: The footnote lists dose as a price factor
- Limitation: Clinical group and pharmacy go unnamed
- Limitation: Supply-duration pricing is not published
What the evidence says about this kind of treatment
The assessment above is about Medro. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who budgets on $199 or $299 and treats the lower lead as a first-order discount.
- Wrong for
- A reader who needs the final price before the prescription step.
The evidence behind what Medro prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Medro compares
| Seller | Who it suits | Go |
|---|---|---|
 EOS Health | Buyers who want the renewal rate printed beside the introductory one, on every plan | See EOS Health → |
 EdgeRx | Readers who want a named compounding pharmacy and will check availability first | See EdgeRx → |
 Citizen Meds | Readers who want the escalation named up front rather than discovered on a statement | See Citizen Meds → |
More GLP-1 telehealth sellers reviews: Blue Haven RXBlue Sky MDBodi EnviBon HealthboostAGErxBoston Medical Group
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Is $99 the monthly price?
- No. It is the first plan with a code applied. The struck $199 is the standing semaglutide rate.
- Does the price rise with the dose?
- The page says no. Its footnote lists dose as a factor. Confirm before checkout.
- Who prescribes?
- A partner medical group. The page does not name it.
- Is Medro legit?
- Medro is a GLP-1 telehealth sellers service. Its stated availability: All 50 states. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
- Is Medro expensive compared with other GLP-1 telehealth sellers?
- Medro publishes a starting figure of $199/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Medro above the median. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.